Analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to post earnings of $0.59 per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for ABIOMED’s earnings, with the highest EPS estimate coming in at $0.66 and the lowest estimate coming in at $0.52. ABIOMED reported earnings per share of $0.33 in the same quarter last year, which indicates a positive year-over-year growth rate of 78.8%. The business is expected to report its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that ABIOMED will report full-year earnings of $2.51 per share for the current fiscal year, with EPS estimates ranging from $2.37 to $2.75. For the next fiscal year, analysts expect that the business will report earnings of $2.70 per share, with EPS estimates ranging from $2.26 to $3.82. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow ABIOMED.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.20. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The company had revenue of $154.00 million during the quarter, compared to analysts’ expectations of $154.00 million. During the same quarter in the prior year, the company posted $0.34 EPS. The business’s revenue was up 34.9% on a year-over-year basis.
Shares of ABIOMED (ABMD) traded down $4.93 during mid-day trading on Friday, hitting $248.20. 426,654 shares of the stock were exchanged, compared to its average volume of 288,812. ABIOMED has a 52 week low of $103.82 and a 52 week high of $255.42. The firm has a market cap of $10,760.00, a PE ratio of 125.35, a price-to-earnings-growth ratio of 3.28 and a beta of 0.36. The company has a current ratio of 5.60, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02.
Several institutional investors have recently made changes to their positions in ABMD. Koch Industries Inc. increased its position in shares of ABIOMED by 40,431.3% during the 2nd quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock worth $794,000 after purchasing an additional 797,305 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of ABIOMED by 102.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock worth $181,553,000 after purchasing an additional 543,793 shares in the last quarter. American Century Companies Inc. increased its position in shares of ABIOMED by 99.0% during the 4th quarter. American Century Companies Inc. now owns 963,517 shares of the medical equipment provider’s stock worth $180,573,000 after purchasing an additional 479,375 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of ABIOMED by 2,219.4% during the 3rd quarter. Wells Fargo & Company MN now owns 364,427 shares of the medical equipment provider’s stock worth $61,443,000 after purchasing an additional 348,715 shares in the last quarter. Finally, FMR LLC acquired a new stake in shares of ABIOMED during the 2nd quarter worth about $32,609,000. Institutional investors and hedge funds own 90.48% of the company’s stock.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.